Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | FDPS | P14324 | 3/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 3/20 | 0.42 |
| ▸ | CES1 | P23141 | 3/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11331130 | 1.00 | CA1 (0.50) | CA1FFAR4FFAR1ACE2FDPS | |
| SCHEMBL8106055 | 1.00 | CA1 (0.50) | CA1FFAR4FFAR1ACE2FDPS | |
| SCHEMBL2486387 | 1.00 | CA1 (0.50) | CA1FFAR4FFAR1ACE2FDPS | |
| SCHEMBL16096992 | 1.00 | CA1 (0.50) | CA1FFAR4FFAR1ACE2FDPS | |
| SCHEMBL4170211 | 1.00 | CA1 (0.50) | CA1FFAR4FFAR1ACE2FDPS | |
| SCHEMBL2482671 | 1.00 | CA1 (0.50) | CA1FFAR4FFAR1ACE2FDPS | |
| SCHEMBL11670081 | 0.98 | CA1 (0.52) | CA1FFAR4FFAR1ACE2FDPS | |
| SCHEMBL7847953 | 0.91 | FFAR4 (0.45) | FFAR4FFAR1LMNAFAAHGPR84 | |
| SCHEMBL2502759 | 0.88 | CA1 (0.48) | CA1FFAR4FFAR1ACE2FDPS | |
| SCHEMBL16702924 | 0.88 | FFAR4 (0.42) | CA1FFAR4FFAR1ACE2FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10230023-B2 | Color converter | BASF SE (DE) | 2019-03-12 | — | — | US | disclosed |
| EP-2718395-B1 | Novel illumination device comprising a colour converter | BASF SE (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-20160284947-A1 | NOVEL COLOR CONVERTER | BASF SE (DE) | 2016-09-29 | — | — | US | disclosed |
| US-9406848-B2 | Color converter | BASF SE (DE) | 2016-08-02 | — | — | US | disclosed |
| EP-2718395-A1 | NOVEL COLOR CONVERTER | BASF SE (DE) | 2014-04-16 | — | — | EP | disclosed |
| WO-2012168395-A1 | NOVEL COLOR CONVERTER | BASF SE (DE) | 2012-12-13 | — | — | WO | disclosed |
| EP-2029573-B1 | DIBENZORYLENETETRACARBOXIMIDES AS INFRARED ABSORBERS | BASF SE (DE) | 2011-10-26 | — | — | EP | disclosed |
| WO-2009037283-A1 | METHOD FOR PRODUCING SUBSTRATES COATED WITH RYLENE TETRACARBOLIC ACID DIIMIDES | BASF SE (DE) | 2009-03-26 | — | — | WO | disclosed |
| US-20090078312-A1 | VERFAHREN ZUR HERSTELLUNG VON MIT RYLENTETRACARBONSAEUREDIIMIDEN BESCHICHTETEN SUBSTRATEN | BASF SE (DE) | 2009-03-26 | — | — | US | disclosed |
| EP-2029573-A1 | DIBENZORYLENETETRACARBOXIMIDES AS INFRARED ABSORBERS | BASF SE (DE) | 2009-03-04 | — | — | EP | disclosed |
| EP-2008319-A2 | LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | BASF SE (DE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007138051-A1 | DIBENZORYLENETETRACARBOXIMIDES AS INFRARED ABSORBERS | BASF SE (DE) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007116001-A2 | LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | BASF SE (DE) | 2007-10-18 | — | — | WO | disclosed |
| EP-1843407-A1 | Liquid crystalline rylenetetracarboxylic acid derivatives and their use | BASF AKTIENGESELLSCHAFT (DE) | 2007-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090078312-A1 | VERFAHREN ZUR HERSTELLUNG VON MIT RYLENTETRACARBONSAEUREDIIMIDEN BESCHICHTETEN SUBSTRATEN | AXIN2, NCSTN, NES | CA1 240/4885FFAR4 3960/4885FFAR1 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.